Centessa Pharmaceuticals (NASDAQ: CNTA) furnishes Q2 2025 financial results press release

Rhea-AI Filing Summary

Centessa Pharmaceuticals plc furnished an earnings update by filing a current report. On August 12, 2025, the company announced its financial results for the quarter ended June 30, 2025 and provided the details in a press release attached as Exhibit 99.1. The report clarifies that this press release is being furnished, not filed, which limits how it is treated under U.S. securities laws.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

FALSE000184790300018479032025-08-122025-08-120001847903us-gaap:CommonStockMember2025-08-122025-08-120001847903cnta:AmericanDepositarySharesMember2025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported): August 12, 2025

CENTESSA PHARMACEUTICALS PLC

(Exact name of Registrant, as specified in its charter)

England and Wales

001-40445

98-1612294

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

3rd Floor

1 Ashley Road

Altrincham

Cheshire

United Kingdom

WA14 2DT

(Address of principal executive offices)

(Zip code)

Registrant's telephone number, including area code: +1 (617) 468-5770

Former name or address, if changed since last report: 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Ordinary shares, nominal value £0.002 per share

CNTA

Nasdaq Stock Market, LLC*

American Depositary Shares, each representing one ordinary share, nominal value £0.002 per share

CNTA

Nasdaq Stock Market, LLC

*Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market, LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On August 12, 2025, Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
99.1			Press Release dated August 12, 2025
104			Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:   August 12, 2025

			By:			/s/ Saurabh Saha
			Name:			Saurabh Saha, M.D., Ph.D.
			Title:			Chief Executive Officer

FAQ

What did Centessa Pharmaceuticals (CNTA) disclose in this 8-K filing?

Centessa Pharmaceuticals plc reported that it announced its financial results for the quarter ended June 30, 2025, and furnished the related press release as Exhibit 99.1.

Which period do the disclosed Centessa (CNTA) results cover?

The announced financial results cover Centessa Pharmaceuticals plc’s quarter ended June 30, 2025.

How were Centessa Pharmaceuticals’ Q2 2025 results provided to investors?

The results were provided through a press release dated August 12, 2025, which is attached to the report as Exhibit 99.1.

Are Centessa’s Q2 2025 results considered filed or furnished with the SEC?

The company states that the information in this report, including Exhibit 99.1, is being furnished and not filed for purposes of Section 18 of the Exchange Act.

Who signed Centessa Pharmaceuticals’ 8-K reporting Q2 2025 results?

The report was signed on behalf of Centessa Pharmaceuticals plc by Saurabh Saha, M.D., Ph.D., Chief Executive Officer.